CG Oncology, Inc. Common stock Cash Flow Conversion Efficiency
CG Oncology, Inc. Common stock cash flow conversion efficiency. Based on the latest financial reports, CG Oncology, Inc. Common stock (CGON) has a cash flow conversion efficiency ratio of -0.048x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-36.22 Million) by net assets ($752.60 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see CG Oncology, Inc. Common stock (CGON) market capitalisation for the company's overall valuation and market capitalisation.
Cash Flow Conversion Efficiency of CG Oncology, Inc. Common stock (2021–2025)
Cash flow conversion efficiency of CG Oncology, Inc. Common stock from 2021 to 2025. This chart illustrates how CG Oncology, Inc. Common stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. View CGON stock price and chart for real-time trading data and today's change.
CG Oncology, Inc. Common stock Cash Flow Conversion Ratio Explained
CG Oncology, Inc. Common stock cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
CG Oncology, Inc. Common stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of CG Oncology, Inc. Common stock ranked by their cash flow conversion efficiency. Review CG Oncology, Inc. Common stock free cash flow to debt ratio to assess the company's free cash flow relative to its total liabilities.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Synnex Technology International Corp
TW:2347
|
-0.266x |
|
Floor & Decor Holdings Inc
NYSE:FND
|
0.068x |
|
TPG Telecom Ltd
AU:TPG
|
0.080x |
|
Enel Generación Chile S.A
SN:ENELGXCH
|
84.843x |
|
CENTESSA PHARMACEUTICALS
F:260
|
-0.148x |
|
PTC Therapeutics Inc
NASDAQ:PTCT
|
0.327x |
|
AutoStore Holdings Ltd
OL:AUTO
|
0.048x |
|
Zhejiang Shuanghuan Driveline Co Ltd
SHE:002472
|
0.029x |
Annual Cash Flow Conversion Efficiency for CG Oncology, Inc. Common stock (2021–2025)
The table below shows the annual cash flow conversion efficiency of CG Oncology, Inc. Common stock from 2021 to 2025. Also see CG Oncology, Inc. Common stock (CGON) total assets for a full breakdown of the balance sheet.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $752.60 Million | $-132.35 Million | -0.176x | -63.84% |
| 2024-12-31 | $733.38 Million | $-78.71 Million | -0.107x | +56.58% |
| 2023-12-31 | $184.79 Million | $-45.68 Million | -0.247x | -3.82% |
| 2022-12-31 | $125.18 Million | $-29.80 Million | -0.238x | +29.81% |
| 2021-12-31 | $40.25 Million | $-13.65 Million | -0.339x | -- |
About CG Oncology, Inc. Common stock
CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company's product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinic… Read more